Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies
暂无分享,去创建一个
Ming Li | Feng Gao | Amit Kumar | Anurag Sethi | S. Gnanakaran | Tanmoy Bhattacharya | Hongmei Gao | Alan S. Lapedes | Michael S. Seaman | Bette T. Korber | Marcus G. Daniels | Myron S. Cohen | Barton F. Haynes | David C. Montefiori | George M. Shaw | Haili Tang | Kelli Greene | A. Lapedes | B. Korber | B. Haynes | Ming Li | D. Montefiori | Tanmoy Bhattacharya | A. Sethi | G. Shaw | M. Daniels | S. Gnanakaran | H. Gao | Amit Kumar | Haili Tang | M. Seaman | Kelli M. Greene | F. Gao | K. Greene | M. Cohen | Hongmei Gao | M. Cohen
[1] J. Sodroski,et al. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein , 1993, Journal of virology.
[2] Renate Kunert,et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. , 2005, Immunity.
[3] M. Luscher,et al. Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response. , 2005, Vaccine.
[4] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[5] Terri Wrin,et al. Novel Ring Structure in the gp41 Trimer of Human Immunodeficiency Virus Type 1 That Modulates Sensitivity and Resistance to Broadly Neutralizing Antibodies , 2009, Journal of Virology.
[6] Peter D. Kwong,et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site , 2005, The Journal of experimental medicine.
[7] David C Montefiori,et al. The role of antibodies in HIV vaccines. , 2010, Annual review of immunology.
[8] Lynn Morris,et al. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? , 2009, Nature Medicine.
[9] Montgomery Slatkin,et al. Modern developments in theoretical population genetics : the legacy of Gustave Malécot , 2002 .
[10] Renate Kunert,et al. Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies , 2005, Science.
[11] Xiping Wei,et al. Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.
[12] K. Lole,et al. Full-Length Human Immunodeficiency Virus Type 1 Genomes from Subtype C-Infected Seroconverters in India, with Evidence of Intersubtype Recombination , 1999, Journal of Virology.
[13] Peter D. Kwong,et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.
[14] J. Overbaugh,et al. Human Immunodeficiency Virus Type 1 V1-V2 Envelope Loop Sequences Expand and Add Glycosylation Sites over the Course of Infection, and These Modifications Affect Antibody Neutralization Sensitivity , 2006, Journal of Virology.
[15] R. Wyatt,et al. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. , 2007, Current pharmaceutical design.
[16] C. Blish,et al. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry , 2007, AIDS.
[17] Shibo Jiang,et al. HIV gp41 C-terminal Heptad Repeat Contains Multifunctional Domains , 2007, Journal of Biological Chemistry.
[18] M. Rosenberg,et al. The N-terminal 31 amino acids of human immunodeficiency virus type 1 envelope protein gp120 contain a potential gp41 contact site , 1991, Journal of virology.
[19] M. Reitz,et al. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site. , 1993, Virology.
[20] John P. Moore,et al. HIV-1 Envelope Triggers Polyclonal Ig Class Switch Recombination through a CD40-Independent Mechanism Involving BAFF and C-Type Lectin Receptors1 , 2006, The Journal of Immunology.
[21] Hideo Matsuda,et al. fastDNAmL: a tool for construction of phylogenetic trees of DNA sequences using maximum likelihood , 1994, Comput. Appl. Biosci..
[22] Peter D. Kwong,et al. Characterization of Human Immunodeficiency Virus Type 1 Monomeric and Trimeric gp120 Glycoproteins Stabilized in the CD4-Bound State: Antigenicity, Biophysics, and Immunogenicity , 2007, Journal of Virology.
[23] B. Korber,et al. Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques , 2006, Journal of Virology.
[24] Richard T. Wyatt,et al. Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables , 2009, Journal of Virology.
[25] J. Mascola,et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. , 1996, The Journal of infectious diseases.
[26] Noah G. Hoffman,et al. Variability in the Human Immunodeficiency Virus Type 1 gp120 Env Protein Linked to Phenotype-Associated Changes in the V3 Loop , 2002, Journal of Virology.
[27] John D. Storey,et al. Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[28] J. Sodroski,et al. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding , 1990, Journal of virology.
[29] Yih-En Andrew Ban,et al. Challenges for structure-based HIV vaccine design , 2009, Current opinion in HIV and AIDS.
[30] Houping Ni,et al. Vaccine-delivered HIV envelope inhibits CD4(+) T-cell activation, a mechanism for poor HIV vaccine responses. , 2007, Blood.
[31] V. Georgiev. Virology , 1955, Nature.
[32] Robyn L Stanfield,et al. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. , 2004, Structure.
[33] Jerome H. Kim,et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.
[34] Tongqing Zhou,et al. Enhanced Exposure of the CD 4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp 120 Domain , 2009 .
[35] Susan Zolla-Pazner,et al. A Variable Region 3 (V3) Mutation Determines a Global Neutralization Phenotype and CD4-Independent Infectivity of a Human Immunodeficiency Virus Type 1 Envelope Associated with a Broadly Cross-Reactive, Primary Virus-Neutralizing Antibody Response , 2002, Journal of Virology.
[36] R. Swanstrom,et al. Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants , 2009, Journal of Virology.
[37] C. Blish,et al. Enhancing Exposure of HIV-1 Neutralization Epitopes through Mutations in gp41 , 2008, PLoS medicine.
[38] Brian T. Foley,et al. Retrieval and on-the-fly alignment of sequence fragments from the HIV database , 2001, Bioinform..
[39] Peter D Kwong,et al. Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. , 2003, Virology.
[40] Susan Zolla-Pazner,et al. A Global Neutralization Resistance Phenotype of Human Immunodeficiency Virus Type 1 Is Determined by Distinct Mechanisms Mediating Enhanced Infectivity and Conformational Change of the Envelope Complex , 2000, Journal of Virology.
[41] G. Quinnan,,et al. Mutations in both gp120 and gp41 Are Responsible for the Broad Neutralization Resistance of Variant Human Immunodeficiency Virus Type 1 MN to Antibodies Directed at V3 and Non-V3 Epitopes , 1998, Journal of Virology.
[42] R. Gallo,et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens , 2007, Proceedings of the National Academy of Sciences.
[43] J. Binley,et al. Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. , 2009, Vaccine.
[44] Tongqing Zhou,et al. Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120 , 2009, Science.
[45] Wei-Yin Loh,et al. Classification and regression trees , 2011, WIREs Data Mining Knowl. Discov..
[46] Lynn Morris,et al. Broad Neutralization of Human Immunodeficiency Virus Type 1 Mediated by Plasma Antibodies against the gp41 Membrane Proximal External Region , 2009, Journal of Virology.
[47] Christos J. Petropoulos,et al. Neutralizing Antibody Responses against Autologous and Heterologous Viruses in Acute versus Chronic Human Immunodeficiency Virus (HIV) Infection: Evidence for a Constraint on the Ability of HIV To Completely Evade Neutralizing Antibody Responses , 2006, Journal of Virology.
[48] John R. Mascola,et al. Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals , 2008, Journal of Virology.
[49] Punnee Pitisuttithum,et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.
[50] Douglas D. Richman,et al. Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors , 2007, Journal of Virology.
[51] Lijun Rong,et al. Role of the HIV gp120 Conserved Domain 1 in Processing and Viral Entry* , 2008, Journal of Biological Chemistry.
[52] Tongqing Zhou,et al. Enhanced Exposure of the CD4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp120 Domain , 2009, Journal of Virology.
[53] B. Korber,et al. Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing , 2008, Journal of Virology.
[54] Xiping Wei,et al. Evidence for Potent Autologous Neutralizing Antibody Titers and Compact Envelopes in Early Infection with Subtype C Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.
[55] Nathan A. Baker,et al. Electrostatics of nanosystems: Application to microtubules and the ribosome , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[56] A. Maerz,et al. Functional Evolution of the HIV-1 Envelope Glycoprotein 120 Association Site of Glycoprotein 41* , 2003, Journal of Biological Chemistry.
[57] Feng Gao,et al. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. , 2006, Virology.
[58] Feng Gao,et al. Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa , 2006, Journal of Virology.
[59] Christos J. Petropoulos,et al. Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus , 2006, The Journal of experimental medicine.
[60] Ying Sun,et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. , 1998, Science.
[61] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[62] Punnee Pitisuttithum,et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. , 2004, The Journal of infectious diseases.
[63] Michael G Hudgens,et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. , 2005, The Journal of infectious diseases.
[64] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[65] Christoph Grundner,et al. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. , 2005, Virology.
[66] W A Hendrickson,et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. , 2000, Structure.
[67] D. Heckerman,et al. Founder Effects in the Assessment of HIV Polymorphisms and HLA Allele Associations , 2007, Science.
[68] William C. Olson,et al. Evaluating the Immunogenicity of a Disulfide-Stabilized, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.
[69] M. Reitz,et al. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope , 1990, Journal of virology.
[70] J. Goudsmit,et al. Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies , 1993, Journal of virology.
[71] Xuesong Yu,et al. Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.
[72] L. Ratner,et al. Human Immunodeficiency Virus Type 1 Coreceptor Switching: V1/V2 Gain-of-Fitness Mutations Compensate for V3 Loss-of-Fitness Mutations , 2006, Journal of Virology.
[73] Barney S. Graham,et al. Neutralizing Antibodies to HIV-1 in Seronegative Volunteers Immunized With Recombinant gp 120 From the MN Strain of HIV-1 , 1994 .
[74] John W. Mellors,et al. Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis , 2005, Journal of Clinical Microbiology.
[75] Peter D. Kwong,et al. The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.
[76] Paul W. H. I. Parren,et al. Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120 , 2003, Journal of Virology.
[77] J. Sodroski,et al. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change , 1994, Journal of virology.
[78] Holly Janes,et al. Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.
[79] E. Bunnik,et al. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure. , 2010, The Journal of general virology.
[80] D. Burton. Antibodies, viruses and vaccines , 2002, Nature Reviews Immunology.
[81] Kenneth H Mayer,et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.
[82] D R Burton,et al. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off , 1997, Journal of virology.
[83] Thomas M. Cover,et al. Elements of Information Theory , 2005 .
[84] Hui Li,et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.
[85] Robyn L Stanfield,et al. Antibody vs. HIV in a clash of evolutionary titans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[86] Rino Rappuoli,et al. Structure-based antigen design: a strategy for next generation vaccines , 2008, Trends in Biotechnology.
[87] J. Shiver,et al. Enhancement of α-Helicity in the HIV-1 Inhibitory Peptide DP178 Leads to an Increased Affinity for Human Monoclonal Antibody 2F5 but Does Not Elicit Neutralizing Responses in Vitro , 2002, The Journal of Biological Chemistry.
[88] David Heckerman,et al. Leveraging Hierarchical Population Structure in Discrete Association Studies , 2007, PloS one.
[89] O. Gascuel,et al. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. , 2003, Systematic biology.
[90] David C Montefiori,et al. Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. , 2010, Virology.
[91] Richard D. Leapman,et al. Oligomeric Structure of the Human Immunodeficiency Virus Type 1 Envelope Protein on the Virion Surface , 2002, Journal of Virology.
[92] Pamela Warner,et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand , 2010, Journal of Family Planning and Reproductive Health Care.
[93] John P. Moore,et al. HIV-1 gp120 Mannoses Induce Immunosuppressive Responses from Dendritic Cells , 2007, PLoS pathogens.
[94] Joseph Sodroski,et al. Increased Neutralization Sensitivity of CD4-Independent Human Immunodeficiency Virus Variants , 2001, Journal of Virology.
[95] Igor A. Sidorov,et al. Concordant Modulation of Neutralization Resistance and High Infectivity of the Primary Human Immunodeficiency Virus Type 1 MN Strain and Definition of a Potential gp41 Binding Site in gp120 , 2003, Journal of Virology.
[96] K. Salzwedel,et al. Sequential CD4-Coreceptor Interactions in Human Immunodeficiency Virus Type 1 Env Function: Soluble CD4 Activates Env for Coreceptor-Dependent Fusion and Reveals Blocking Activities of Antibodies against Cryptic Conserved Epitopes on gp120 , 2000, Journal of Virology.
[97] Lijun Rong,et al. Alanine Scanning Mutants of the HIV gp41 Loop* , 2005, Journal of Biological Chemistry.
[98] David C Montefiori,et al. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates , 2006, Expert review of vaccines.
[99] Peter D. Kwong,et al. Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope , 2004, Journal of Virology.
[100] Lynn Morris,et al. Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C , 2008, Journal of Virology.
[101] Jessica Yu,et al. Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. , 2007, Vaccine.
[102] S. Gnanakaran,et al. Unique Mutational Patterns in the Envelope α2 Amphipathic Helix and Acquisition of Length in gp120 Hypervariable Domains Are Associated with Resistance to Autologous Neutralization of Subtype C Human Immunodeficiency Virus Type 1 , 2007, Journal of Virology.
[103] John R Mascola,et al. Defining the protective antibody response for HIV-1. , 2003, Current molecular medicine.
[104] Mark Connors,et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies , 2007, Nature Medicine.
[105] Christoph Grundner,et al. Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.
[106] J. Sodroski,et al. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.
[107] A. Gronenborn,et al. Three‐dimensional solution structure of the 44 kDa ectodomain of SIV gp41 , 1998, The EMBO journal.
[108] J. Robinson,et al. Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites , 1996, Journal of virology.
[109] D. Montefiori,et al. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. , 2000, AIDS research and human retroviruses.
[110] Tongqing Zhou,et al. Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment , 2009, Journal of Virology.
[111] Yong He,et al. Human Immunodeficiency Virus (HIV) gp41 Escape Mutants: Cross-Resistance to Peptide Inhibitors of HIV Fusion and Altered Receptor Activation of gp120 , 2005, Journal of Virology.
[112] Lynn Morris,et al. Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors , 2009, Journal of Virology.
[113] Wayne C Koff,et al. HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.
[114] J. Sodroski,et al. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. , 2000, AIDS research and human retroviruses.
[115] Eric Bauer,et al. An Empirical Comparison of Voting Classification Algorithms: Bagging, Boosting, and Variants , 1999, Machine Learning.
[116] J. Sodroski,et al. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. , 1987, Science.
[117] Tongqing Zhou,et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.
[118] P. S. Kim,et al. HIV Entry and Its Inhibition , 1998, Cell.
[119] Shibo Jiang,et al. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains , 2008, Proceedings of the National Academy of Sciences.
[120] Garrett M. Morris,et al. Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design , 2001, Science.
[121] M Anthony Moody,et al. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. , 2006, Human antibodies.
[122] J. Sodroski,et al. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein , 1991, Journal of virology.
[123] S. Harrison,et al. Structural basis for membrane fusion by enveloped viruses. , 1999, Molecular membrane biology.
[124] J. Sodroski,et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.
[125] Renate Kunert,et al. Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.
[126] Tongqing Zhou,et al. Structure-Based Stabilization of HIV-1 gp120 Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site , 2009, PLoS pathogens.
[127] Bette T. Korber,et al. Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission , 2004, Science.
[128] M. Reitz,et al. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene , 1988, Cell.
[129] Bette Korber,et al. Structure of a V3-Containing HIV-1 gp120 Core , 2005, Science.
[130] S Gnanakaran,et al. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. , 2009, Virology.
[131] Joseph Sodroski,et al. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. , 2002, AIDS research and human retroviruses.
[132] J. Sodroski,et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.
[133] Don C. Wiley,et al. Structure of an unliganded simian immunodeficiency virus gp120 core , 2005, Nature.